Sitagliptin/Ertugliflozin

N/A

Report date: 2022/03/09 20:00:20

Base Information

Drug NameSitagliptin/Ertugliflozin
Drug Alias NameSteglujan
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/12/19
Country/TerritoryUnited StatesEU
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD24
Related LinksN/A